ALKERMES | Resultado Líquido



Net Income Alterar Data
AbbVie USD -22000000 1.58B 2024-12
Acadia Pharmaceuticals USD 143.74M 110.98M 2024-12
ALKERMES USD 367.07M 274.69M 2024-12
Amgen USD 627M 2.2B 2024-12
Biogen USD 266.7M 121.8M 2024-12
BioMarin Pharmaceutical USD 124.94M 18.86M 2024-12
Bristol-Myers Squibb USD 72M 1.14B 2024-12
Eli Lilly USD 4.41B 3.44B 2024-12
Gilead Sciences USD 1.78B 529M 2024-12
Intra Cellular Therapies USD -16885000 9.44M 2024-12
Ionis Pharmaceuticals USD -104349000 36.13M 2024-12
J&J USD 3.43B 737M 2024-12
Malin Corporation EUR 0 1.1M 2024-06
Merck USD 3.74B 586M 2024-12
Neurocrine Biosciences USD 103.1M 26.7M 2024-12
Otsuka Holdings JPY 151.45B 67.57B 2024-12
Pfizer USD 410M 4.06B 2024-12
Regeneron Pharmaceuticals USD 917.7M 422.9M 2024-12
Vertex Pharmaceuticals USD 913M 132.4M 2024-12



ALKERMES Resultado Líquido - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2025.